Sponsored By
THE WINNERS HAVE BEEN ANNOUNCED!
Now in its 19th year, the Scrip Awards brings together over 400 industry leaders to celebrate and recognize the very best innovations and achievements in global biopharma. Winners will be celebrated across 14 categories, covering the whole spectrum of advancements, from Best New Drug, Community Partnership of the Year, Best Contract Research Organization as well as a new category for 2023, Best Oncology R&D Advance.
All entries will be carefully reviewed by an independent Judging Panel - a group of senior industry experts from around the world, handpicked for their experience and objectivity. This prestigious annual event of networking and celebration will incorporate a gala black-tie dinner and Awards ceremony, on Thursday 16 November.
Key details
Thursday, 16 November, 2023
The Dorchester, 53 Park Lane, London W1K 1QA
The Awards for the Best Contract Research Organization acknowledge the critical role that CROs play in drug development. Clinical outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials. The Awards for CROs are split into two sister categories to separate the larger full-service providers from those smaller CROs that provide specialist services to their clients.
WINNER
- Parexel
FINALISTS
- Altasciences
- CMIC
- Fortrea
- ICON
- Parexel
- ProPharma
- The PPD clinical research business of Thermo Fisher Scientific
- WuXi AppTec
WHO COULD ENTER
This Award is for the companies who provide the full range of clinical research services and they will be judged on the quality of these services and relationships the firms have built with their clients. It will pay particular attention to the innovative patient recruitment strategies the CRO has brought to the deal. To qualify, candidates must draw on their achievements in the year between 1 June 2022 - 30 June 2023.
The Awards for the Best Contract Research Organization acknowledge the critical role that CROs play in drug development. Clinical outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials. The Awards for CROs are split into two sister categories to separate the larger full-service providers from those smaller CROs that provide specialist services to their clients.
WINNER
- CluePoints
FINALISTS
- Agilex Biolabs
- Avance Clinical
- Bioforum
- CluePoints
- CTI Clinical Trial & Consulting
- Fortrea
- George Clinical
- MMS Holdings
WHO COULD ENTER
This Award for those companies who provide niche services to their clients will be judged on the quality of these services and relationships they have built with their clients. To qualify, candidates must draw on their achievements in the year between 1 June 2022 - 30 June 2023.
The Best New Drug Award recognizes excellence in pharmaceutical development. Launching innovative new products is the most important function of the industry, and a successful new drug launch marks the culmination of years of risky and expensive R&D. In this category, the judges will be looking for the small-molecule or biological product that was approved in its first market worldwide during the qualifying period that represents the best therapeutic advance in its area.
WINNER
- Eisai’s Leqembi (lecanemab) for Alzheimer's disease
FINALISTS
- Eisai’s Leqembi (lecanemab) for Alzheimer's disease
- Ferring Pharmaceuticals’ Rebyota (fecal microbiota, live) for recurrent Clostridioides difficile infection
- Gamida Cell’s Omisirge (omidubicel-onlv) for use in hematopoietic stem cell transplants
- Genmab and AbbVie’s Epkinly (epcoritamab) for diffuse large B-cell lymphoma
- Pharming's Joenja (leniolisib) for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome
- Reata Pharmaceuticals' Skyclarys (omaveloxolone) for Friedreich's ataxia
- Stemline Therapeutics (Menarini)’s Orserdu (elacestrant) for breast cancer
WHO COULD ENTER
All recently launched new active substances, including small molecules, biologicals or vaccines, are eligible to enter so long as they were first licensed in any market between 1 June 2022 - 30 June 2023. Generic and biosimilar products are not eligible for this Award.
Entrants must have played a role in the development of the nominated product, and all parties to joint ventures should be disclosed in the application.
This new Scrip Award seeks to recognize early clinical advances in oncology made by small biopharma companies. The great strides seen in cancer therapies in recent years often had their genesis in the labs of specialist firms. We are looking to reward companies that are exploiting new knowledge in cancer cell biology and the tumor microenvironment to forge new paths to tackle the disease, for instance by developing novel therapeutic strategies in immuno-oncology, gene and cell therapies and new targeted agents.
This category is aimed at clinical-stage oncology firms pioneering new approaches in the treatment of cancer that have shown proof of concept in early (Phase I or II) clinical trials and have candidates moving forward in the development pathway.
WINNER
- AffyImmune Therapeutics’ AIC100 ICAM-1 targeting CAR T cell therapy
FINALISTS
- AffyImmune Therapeutics’ AIC100 ICAM-1 targeting CAR T cell therapy
- Arvinas and Pfizer’s oral PROteolysis TArgeting Chimera (PROTAC) ER degrader vepdegestrant for breast cancer
- Avacta Therapeutics’ AVA6000 pre|CISION tumour-targeted chemotherapy
- Immuneering’s deep cyclic inhibition candidate IMM-1-104 for advanced RAS-mutant solid tumors
- Kura Oncology’s menin inhibitor ziftomenib for multiple genetic subsets of acute myeloid leukemia
- MSD/Moderna’s mRNA-4157/V940 investigational individualized neoantigen therapy
WHO COULD ENTER
To be eligible, results for the study or program under nomination must have been released between 1 June 2022 – 30 June 2023. Entrants must have played a role in the early phase research, and all joint parties must be disclosed in the application.
This Award seeks to recognize success in a clinical trial of a new drug product (biological or chemical) that is expected to lead to an advance in healthcare. This might include the first demonstration of a clear clinical effect for a new drug in an area of unmet medical need, a pivotal study of a new drug with a breakthrough mechanism of action, or a major study of a potential new or expanded indication for an already marketed product. The product involved need not yet be approved, but the judges will be looking for innovation, clear proof of benefit and potential commercial reward. To be eligible, the study in question must have been presented for peer review at a major medical meeting or been published in a scientific journal between 1 June 2022 - 30 June 2023.
WINNER
- Eisai’s Phase III Clarity AD study of Leqembi (lecanemab) in early Alzheimer’s disease
FINALISTS
- Achieve Life Sciences’ Phase III ORCA-2 study of cytisinicline in smoking cessation
- Alexion’s Phase III CHAMPION-NMOSD trial of ravulizumab in adults with neuromyelitis optica spectrum disorder
- Avidity Biosciences’ Phase I/II MARINA trial of AOC 1001 in myotonic dystrophy type 1
- Eisai’s Phase III Clarity AD study of Leqembi (lecanemab) in early Alzheimer’s disease
- Karuna Therapeutics' Phase III EMERGENT-3 trial of KarXT (xanomeline-trospium) in schizophrenia
- Servier Pharmaceuticals’ Phase III INDIGO study of vorasidenib in glioma
- US Specialty Formulations/VaxForm’s Phase I study of QYNDR-RBD oral COVID-19 vaccine CoV2-OGEN1
- Verona Pharma’s Phase III ENHANCE trial program of ensifentrine in chronic obstructive pulmonary disease
WHO COULD ENTER
To be eligible, the study in question must have been presented for peer review at a major medical meeting or been published in a scientific journal between 1 June 2022 - 30 June 2023.
Entrants must have played a role in the clinical study, and all joint parties must be disclosed in the application.
Scrip’s Executive of the Year Award is designed to acknowledge excellence in the leadership of large and small pharmaceutical and biotechnology companies.
WINNER
- Paul Hudson, CEO of Sanofi
FINALISTS (Commercial-Stage Companies)
- Renée Aguiar-Lucander, CEO of Calliditas
- Paul Hudson, CEO of Sanofi
- Harren Jhoti, CEO of Astex Pharmaceuticals
- John V Oyler, chairman, co-founder and CEO of BeiGene
- Richard Saynor, CEO of Sandoz
- Umang Vohra, managing director and global CEO of Cipla
FINALISTS (Developmental-Stage Companies) - sponsored by Dalriada Drug Discovery
- Stéphane Boissel, CEO of SparingVision
- Stephen Dale, chief medical officer of Kura Oncology
- Andrew Hopkins, CEO and founder of Exscientia
- James Peyer, CEO and founder of Cambrian Bio
- Jorge Santos Da Silva, CEO and co-founder of MoonLake Immunotherapeutics
- David Zaccardelli, president and CEO of Verona Pharma
WHO COULD ENTER
This year’s winner will be the executive who has exhibited exemplary leadership throughout the year from 1 June 2022 - 30 June 2023. To be eligible for this year’s Award, entrants must hold a C-suite executive position. Candidates must be employed by the company at the time of nomination.
Licensing is vital both in helping to keep pharma’s pipelines replenished and in generating income for smaller firms. Deals considered here are those that involve the licensing of a particular drug, project or group of closely related drugs/projects from one company to another for further development and/or marketing. Please note, it does not include more involved partnerships between companies to explore particular therapeutic strategies (see Criteria for the Best Partnership Alliance)
WINNER
- Nimbus Therapeutics and Takeda for the worldwide development and commercialization of TAK-279
FINALISTS
- Akeso and Summit Therapeutics for the development and commercialization of ivonescimab in the US, Canada, Europe, and Japan
- AstraZeneca and KYM Biosciences for the worldwide development, manufacture and commercialization of CMG901
- HUTCHMED and Takeda for the worldwide development and commercialization of fruquintinib outside mainland China, Hong Kong and Macau
- Nimbus Therapeutics and Takeda for the worldwide development and commercialization of TAK-279
- Ventus Therapeutics and Novo Nordisk for the development and commercialization of VENT-01
- Zymeworks and Jazz Pharmaceuticals for the development and commercialization of zanidatamab in the US, Europe, Japan and all other territories except for specific Asia/Pacific markets
WHO COULD ENTER
To qualify, licensing deals must have been closed between 1 June 2022 - 30 June 2023.
This category will acknowledge and celebrate the outstanding scientific or technological breakthrough which the judging panel believes has the potential to be transformative in the discovery or development of new medicines.
WINNER
- Quris-AI Closes the Clinical Prediction Gap
FINALISTS
- Astex Pharmaceuticals’ Pyramid fragment-based drug discovery platform
- Constructive Bio’s genome synthesis technologies
- OMass Therapeutics’ OdyssION drug discovery platform
- Optibrium’s StarDrop Metabolism module
- PhoreMost’s SITESEEKER technology
- Quris-AI Closes the Clinical Prediction Gap
- Seamless Therapeutics’ recombinase gene editing platform
- Zephyr AI’s artificial intelligence platform
WHO COULD ENTER
Start-up pharma/biotech companies wishing to enter must have designed, delivered and launched the innovation (alone or with a partner), and all parties to any joint development activities must be disclosed in the application.
Scrip’s Best Partnership Alliance Award recognizes the importance of pharmaceutical and/or biotech companies working together to develop new medicines from the earliest stages. This category seeks to reward innovative partnerships between companies in which they share the risks and rewards inherent in exploring novel therapeutic strategies and developing new drugs.
WINNER
- AstraZeneca with Quell Therapeutics for the research, global development and commercialization of T-regulatory cell therapies in Type 1 diabetes and inflammatory bowel disease
FINALISTS
- AstraZeneca with Neogene Therapeutics for the development of T-cell receptor cell therapies in cancer
- AstraZeneca with Quell Therapeutics for the research, global development and commercialization of T-regulatory cell therapies in Type 1 diabetes and inflammatory bowel disease
- Merck KGaA and Aqilion for the discovery, development and commercialization of small-molecule transforming growth factor-β-activated kinase 1 inhibitors for chronic inflammatory diseases
- Ovid Therapeutics with Graviton Bioscience for ROCK2 inhibitor compounds in rare CNS diseases
- Sonoma Biotherapeutics and Regeneron Pharmaceuticals for the discovery, development and commercialization of novel regulatory T-cell therapies for autoimmune diseases
- The University of Texas MD Anderson Cancer Center and National Resilience’s CTMC, a standalone joint venture for cell therapies in cancer
WHO COULD ENTER
The judges will be focusing on deals that require strong strategic input from both partners, involving R&D, business development or joint marketing/promotion. They are looking for those deals that are the most mutually beneficial, have the most strategic potential, and are innovative in their structure. Partnerships must have been announced, or have achieved a significant milestone, between 1 June 2022 - 30 June 2023, and entrants should be able to show some benefits arising from the deal.
Please note, this Award does not cover the licensing of a particular drug, project or group of closely related drugs/projects from one company to another for further development and/or marketing (see Criteria for Licensing Deal of the Year).
The biotech industry’s entrepreneurial spirit and cutting-edge science have transformed the research and development of medicines in the past few decades. This Award honours outstanding achievement by biotech companies over the qualifying 12 months.
WINNER
- MoonLake Immunotherapeutics
FINALISTS
- Affini-T Therapeutics
- Calliditas Therapeutics
- Complement Therapeutics
- Ionis Pharmaceuticals
- MoonLake Immunotherapeutics
- Pharming
- PTC Therapeutics
- Verona Pharma
WHO COULD ENTER
The winner of the Biotech Company of the Year Award will be the biotech firm that has achieved the most in the 12 months between 1 June 2022 - 30 June 2023
WINNER
- Eli Lilly and Company
The Pharma Company of the Year Award honors outstanding achievements by pharmaceutical companies over the qualifying 12 months between 1 June 2022 - 30 June 2023.
This special Award is chosen by Scrip’s senior editorial team, based on a variety of key metrics: This special Award is chosen by Scrip’s senior editorial team. The winner will be announced on the night of the Scrip Awards.
The winner of this Award will be an exceptional individual with a consistent history of service, above and beyond the call of duty, throughout their career. This prestigious international Award will go to someone who has had a distinguished career in the biotech or pharmaceutical arena, primarily within industry.
WINNER
- Jeremy Levin, Chairman and CEO, Ovid Therapeutics
WHO COULD ENTER
Nominees may be retired or semi-retired but will still be active in the industry in some capacity. For this special Award, candidates must be nominated by a third party.
SEE ALL SCRIP AWARDS 2023 SHORTLISTED ENTRIES BELOW
HEADLINE SPONSOR
ICON plc is a world-leading healthcare intelligence and clinical research organisation, with over 38,000 employees in 93 locations in 46 countries around the world, headquartered in Dublin. We advance clinical research by providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device, and government and public health organisations. Our services span the entire lifecycle of product development, from molecule to medicine, across a broad range of therapeutic areas. We develop new innovations, drive emerging therapies forward, and improve patient lives.
.png?la=ja-JP&h=948&w=2254&hash=2A9D8AEC75DB290C19468469B16F92DE){kind=logo}
From specialty biotechs to multinational pharmaceutical companies to nonprofits and academic medical centers, we partner with clients across the clinical trials continuum, from start to finish. Our approach is to provide scalable solutions based on the specific needs of each client.
This year Dalriada turns six. That’s six years of driving innovative small-molecule programs from concept to IND. Over that time, our insightful team and our capabilities have significantly grown, and we now offer global clients a wide breadth of top-notch drug discovery services that includes medicinal and computational chemistry, ADME, biological sciences, proteomics, structural biology, preclinical development, and other disciplines.
We are disease-area agnostic but hold deep experience across multiple disease areas. We additionally have major technical strengths in areas such as covalent inhibition and protein degradation.
In today’s drug discovery marketplace we provide unique value and commercial offering. We invite potential clients to visit our newly enhanced website, www.dalriadatx.com, and to connect with us for exploratory conversations.
Latham’s cross-disciplinary healthcare and life sciences team delivers insightful, practical guidance and sophisticated representation to a full spectrum of companies across the globe, on every type of transaction or dispute a company may face. Many of us hold advanced scientific degrees and have served in senior positions as government regulators, C-Suite executives in leading healthcare and life sciences companies, as well as serving as primary outside counsel for key industry associations.
We regularly navigate commercial and regulatory issues related to the Food and Drug Administration, the Patent Trial and Appeals Board, the European Medicines Agency, the European Commission, and other state, and federal agencies in the US and across Europe.
Website: https://www.lw.com
OUR 2023 SUPPORTER
Pharma Ignite brings you the most up-to-date and informed intelligence in the industry. Our network of industry-leading analysts and partners is pursuing new intelligence in the core areas of life sciences using Citeline’s suite of insights products and services - all of which has the power to fuel your organization and projects.
We provide cutting-edge lead generation and brand programmes to help you reach and collaborate with audiences across industry events and digital platforms.
PREVIOUS SCRIP AWARD CEREMONIES
Scrip Awards 2022
Headline sponsor
